In this online, self-learning activity:
Chronic lymphocytic leukemia (CLL) is a diverse group of hematologic cancers in which B-cells accumulate in the blood, bone marrow, and lymphatic tissue, constituting as absolute lymphocytosis of mature-appearing lymphocytes with an appropriate immunophenotype. CLL is an indolent disease and often goes undetected for some time. Patients may present clinically with a range of constitutional symptoms usually range from lymphadenopathy, night sweats, weight loss, weakness, and fever. Staging systems take into account a variety of factors, including lymphadenopathy, splenomegaly, hepatomegaly, and the presence and severity of cytopenias, while a patient’s prognosis is impacted by gene mutation status and cytogenetic and chromosomal abnormalities. Both the presentation and progression of CLL vary between patients, although patients diagnosed in advanced or high-risk stages of the disease have a median survival of less than four years.
The following HCPs: Medical oncologists and hematologists; physician assistants, nurse practitioners, and pharmacists who practice in oncology; and other healthcare professionals who commonly encounter patients with CLL.
Commercial Support Disclosure: This program is supported by an educational grant from Merck.
This activity is free of charge.
Release Date: January 20, 2023 -- Expiration Date: January 20, 2024
Faculty: Sikander Ailawadhi, MD
Faculty introduction, disclosures |
Introductory content and review of CLL
|
Updates in treatment in patients with CLL
|
Summary, conclusions, and best practice recap |
By the end of the session the participant will be able to:
ACCME Activity #202379999
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through ScientiaCME. ScientiaCME is accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation: ScientiaCME designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™ toward the AMA Physician's Recognition Award. Physicians should only claim credit commensurate with the extent of their participation in the activity.
ABIM MOC Recognition Statement: Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
ABIM MOC Credit Type: Medical Knowledge
Physicians: For maintenance of certification (MOC) points, you must enter your board certification ID # and birth date correctly. It is the learner's responsibility to provide this information completely and accurately at the completion of the activity. Without providing it, the learner will NOT receive MOC points for this activity. By providing this data, you acknowledge that it will be shared with ACCME and the applicable certifying board. Please note: Not all activities on this site provide MOC points. If this activity does not specify that it provides MOC points in this section, then it does NOT provide MOC points. This activity provides MOC points only for ABIM and ABP.
Pharmacists
ScientiaCME is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.0 contact hours (0.1 CEUs) of continuing pharmacy education credit. Proof of participation will be posted to your NABP CPE profile within 4 to 6 weeks to participants who have successfully completed the post-test. Participants must participate in the entire presentation and complete the course evaluation to receive continuing pharmacy education credit. ACPE #0574-0000-23-004-H01-P. This is an Application (A)-type activity.
Pharmacists: You must enter your NABP # and birth date correctly so that proof of participation can be posted to your NABP CPE profile. It is the learner's responsibility to provide this information completely and accurately at the completion of the activity. Without providing it, the learner will NOT receive CPE credit for this activity.
Nurse Practitioners (NPs): The American Academy of Nurse Practitioners accepts AMA PRA Category 1 Credit(s)™ from organizations accredited by the ACCME. ScientiaCME will provide NPs who successfully complete each activity with a certificate of participation indicating that the activity was designated for AMA PRA Category 1 Credit(s)™.
As a provider of continuing medical education, it is the policy of ScientiaCME to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, faculty and educational planners must disclose any significant relationships with commercial interests whose products or devices may be mentioned in faculty presentations, and any relationships with the commercial supporter of the activity. The intent of this disclosure is to provide the intended audience with information on which they can make their own judgments. Additionally, in the event a conflict of interest (COI) does exist, it is the policy of ScientiaCME to ensure that the COI is resolved in order to ensure the integrity of the CME activity. For this CME activity, any COI has been resolved thru content review by ScientiaCME.
Disclosure of Faculty: Sikander Ailawadhi, MD, Assistant Professor of Clinical Medicine, Mayo Clinic, has received financial compensation for research and/or consulting work from Beigene, Sanofi, Takeda, BMS, GSK, Pharmacyclics, Amgen, Janssen, Astra Zeneca, Regeneron, Cellectar, Xencor, Abbvie, Ascentage.
Disclosures of Educational Planners: Charles Turck, PharmD, BCPS, BCCCP, President of ScientiaCME, has no relevant financial disclosures.
Faculty WILL NOT discuss off-label uses.
All relevant financial relationships have been mitigated.
ScientiaCME adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Commercial Support Disclosure: This program is supported by an educational grant from Merck.
*Required to view Printable PDF Version
Please take a few minutes to participate in the optional pre-test. It will help us measure the knowledge gained by participating in this activity.
Myeloma bone disease: Monitoring and management
Prediction and management of bone complications in prostate cancer